Passage Bio Inc

NASDAQ:PASG  
19.57
+0.87 (+4.65%)
Regulatory, Other Pre-Announcement

Passage Bio Reports Third Quarter 2020 Financial Results And Recent Business Highlights

Published: 11/10/2020 12:57 GMT
(PASG) - Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights.
Q3 Loss per Share $0.63.
Q3 Earnings per Share Estimate $-0.76 -- Refinitiv Ibes Data (analyst estimates).
Dosing for First Patient in Pbgm01 Phase 1/2 Trial Anticipated in 1q2021.
Phase 1/2 Clinical Trials for Ftd-grn and Krabbe Expected to Initiate in 1h21.
Co Remains Confident to Receive FDA Clearance for Investigational New Drug Application for Pbgm01.